These are top 10 stocks traded on the Robinhood UK platform in July
SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR), a clinical-stage biotech with a market capitalization of $119 million, will host an investor call tomorrow to present top-line data from the 16-week induction period of its ongoing global Phase 2b REZOLVE-AD clinical trial, according to a company press release. According to InvestingPro data, the stock has experienced an 8% decline over the past week, highlighting investor sensitivity to trial outcomes.
The trial is evaluating rezpegaldesleukin, an investigational regulatory T-cell proliferator, for the treatment of moderate-to-severe atopic dermatitis. The webcast is scheduled for Tuesday at 8:15 a.m. ET.
Nektar, a clinical-stage biotechnology company focused on developing novel immunology therapies, will release the data in a morning press release prior to the presentation.
Rezpegaldesleukin, also known as REZPEG or NKTR-358, is the company’s lead product candidate and is described as a first-in-class regulatory T cell stimulator. The compound is currently being evaluated in two Phase 2b clinical trials - one for atopic dermatitis and another for alopecia areata.
The company’s pipeline includes several other investigational compounds, including a preclinical bivalent tumor necrosis factor receptor type II antibody, bispecific programs NKTR-0165 and NKTR-0166, and NKTR-422, a modified hematopoietic colony stimulating factor protein.
Nektar is headquartered in San Francisco and is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to enhance the immune system’s ability to fight cancer, in several ongoing clinical trials.
In other recent news, Nektar Therapeutics reported financial results for the first quarter of 2025, which fell short of analyst expectations. The company posted an earnings per share (EPS) of -$0.24, missing the forecasted -$0.16, and generated revenue of $10.5 million, below the anticipated $16.31 million. Despite this, Nektar maintains a strong cash position, with $220.7 million in cash and equivalents, expected to support operations into the fourth quarter of 2026. H.C. Wainwright and BTIG both reiterated Buy ratings for Nektar, with price targets of $6.50 and $4.00, respectively, highlighting optimism about upcoming clinical trial results. Nektar is on track to announce topline results from its Phase 2b trials for REZPEG in atopic dermatitis and alopecia areata in June and December 2025, respectively. These trials are considered significant milestones, with analysts expressing confidence in the drug’s potential based on earlier positive outcomes. Additionally, Nektar is advancing its pipeline with plans to submit an Investigational New Drug (IND) application for NKTR-0165 by the end of 2025. The company is also managing ongoing litigation with Lilly, which poses potential risks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.